Urogen Pharma (NASDAQ:URGN) Posts Earnings Results, Misses Estimates By $0.14 EPS

Urogen Pharma (NASDAQ:URGN) issued its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.14), FiscalAI reports. The firm had revenue of $89.00 million during the quarter, compared to the consensus estimate of $89.92 million.

Here are the key takeaways from Urogen Pharma’s conference call:

• ZUSDURI revenue reached $68 million, up 35% sequentially. Prescribers increased to 662, repeat prescribers rose to 331, and management expects further quarter-over-quarter revenue growth in Q4 despite typical holiday seasonality.
• Management said the launch remains early, with broad adoption still developing: repeat prescribers were 50% of total writers, and the company estimated only a little over 10% of its core target urologists had prescribed ZUSDURI. It plans to expand patient-awareness efforts around mid-2027, while citing reimbursement confidence and practice workflows as adoption hurdles.
• JELMYTO revenue was $21 million, down from $22 million in Q2, and full-year revenue guidance was revised to approximately $90 million. The company cited a one-time $1.5 million gross-to-net adjustment and competition from clinical trials that is weighing on patient starts.
• The FDA accepted UGN-103’s NDA and set a June 14, 2027 PDUFA date; UroGen plans a potential launch in 2028, subject to approval and a permanent J-code. The company also expects to complete UGN-104 enrollment by year-end or early 2027, and has dosed the first patient in the UGN-501 Phase I trial.
• UroGen reported $90.5 million in cash and marketable securities, plus $117 million in accounts receivable, and management expects profitability and positive cash flow in Q4 2026. Operating expenses are now expected toward the upper end of the $260 million–$270 million guidance range.

Urogen Pharma Stock Down 10.5%

Urogen Pharma stock opened at $25.73 on Friday. The company has a market capitalization of $1.26 billion, a PE ratio of -19.49 and a beta of 1.68. Urogen Pharma has a 12-month low of $16.50 and a 12-month high of $50.81. The firm’s fifty day moving average is $39.20 and its 200 day moving average is $31.50.

Insiders Place Their Bets

In other Urogen Pharma news, General Counsel Jason Smith sold 1,519 shares of Urogen Pharma stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total value of $64,618.26. Following the completion of the sale, the general counsel directly owned 53,141 shares of the company’s stock, valued at approximately $2,260,618.14. The trade was a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 871 shares of Urogen Pharma stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total transaction of $37,383.32. Following the completion of the sale, the insider directly owned 59,882 shares of the company’s stock, valued at approximately $2,570,135.44. This trade represents a 1.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 65,269 shares of company stock worth $3,037,646. 4.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on URGN. Oppenheimer set a $60.00 price target on shares of Urogen Pharma in a research report on Thursday. TD Cowen increased their price objective on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. The Goldman Sachs Group reissued a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a research note on Wednesday, July 15th. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Urogen Pharma in a report on Monday, October 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Thursday, October 15th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $53.38.

About Urogen Pharma

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.